Emergence of long-term surviving patients with the introduction of Cetuximab in recurrent/metastatic disease of squamous cell carcinoma of head and neck

Approximately 30% of all patients diagnosed with Squamous Cell Carcinoma of the Head and Neck (SCCHN) will ultimately have recurrent disease or distant metastasis that render them unable to receive radical treatment. Systemic palliative therapy is then the treatment of choice, achieving a median overall survival of 10months with the combination of chemotherapy (CT) and Cetuximab [1].

from #ENT via xlomafota13 on Inoreader http://ift.tt/24s8SzE
via IFTTT